14 Days Historical Data
| Date | Opening price | Closing price | Minimum price | Maximum price |
| 2022-03-11 | Open: 1.235 | Close: 1.180 | Low: 1.180 | High: 1.235 |
| 2022-03-10 | Open: 1.290 | Close: 1.260 | Low: 1.230 | High: 1.290 |
| 2022-03-09 | Open: 1.215 | Close: 1.270 | Low: 1.215 | High: 1.300 |
| 2022-03-08 | Open: 1.050 | Close: 1.210 | Low: 1.050 | High: 1.220 |
Should you hold progenity (prog) stock?
Apr 24, 2022 · Their forecasts range from $2.00 to $42.00. On average, they anticipate Progenity's stock price to reach $11.00 in the next year. This suggests a possible upside of 1,143.6% from the stock's current price. View analysts' price targets for Progenity or view top-rated stocks among Wall Street analysts.
Will prog stock price drop/fall?
Apr 12, 2022 · On average, they expect PROG's stock price to reach $51.33 in the next year. This suggests a possible upside of 78.0% from the stock's current price. View analysts' price targets for PROG or view top-rated stocks among Wall Street analysts .
Where can I buy shares of prog?
(NASDAQ: PROG) PROGENITY's current Earnings Per Share (EPS) is -$2.57. On average, analysts forecast that PROG's EPS will be -$0.49 for 2022, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.49.
What is the upside for prog's share price?
14 rows · Mar 28, 2022 · At Walletinvestor.com we predict future values with technical analysis for wide selection of ...
Is PROG a good stock to buy?
Will PROG stock go up?
...
Predicted Opening Price for Progenity, Inc. of Monday, May 9, 2022.
| Fair opening price May 9, 2022 | Current price |
|---|---|
| $0.88 | $0.88 (Overvalued) |
Should I sell Progenity stock?
Is Progenity stock a buy?
Will camber energy stock go up?
Why is Progenity stock down?
What is a stock squeeze?
What is PROG price target?
Based on 2 Wall Street analysts offering 12 month price targets for Progenity in the last 3 months. The average price target is $23.00 with a high forecast of $42.00 and a low forecast of $4.00.
What is the short interest on PROG?
Is Progenity a buy right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progenity in the last twelve months. There are currently...
Are investors shorting Progenity?
Progenity saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 18,380,000 shares, an i...
When is Progenity's next earnings date?
Progenity is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for Progenity .
How were Progenity's earnings last quarter?
Progenity, Inc. (NASDAQ:PROG) released its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the q...
What price target have analysts set for PROG?
6 brokers have issued 1-year target prices for Progenity's stock. Their forecasts range from $2.00 to $42.00. On average, they expect Progenity's s...
Who are Progenity's key executives?
Progenity's management team includes the following people: Dr. Harry Stylli , Founder, CEO & Chairman (Age 59, Pay $398.82k) Mr. Eric d'Esparbes...
Who are some of Progenity's key competitors?
Some companies that are related to Progenity include Viridian Therapeutics (VRDN) , DermTech (DMTK) , Personalis (PSNL) , Genetron (GTH) , Ren...
What other stocks do shareholders of Progenity own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Progenity investors own include Advanced Micro Devices (AM...
When did Progenity IPO?
(PROG) raised $100 million in an IPO on Friday, June 19th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Piper Sa...
Is PROG a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROG in the last year. There are currently 1 hold rating...
When is PROG's next earnings date?
PROG is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for PROG .
How were PROG's earnings last quarter?
PROG Holdings, Inc. (NYSE:PRG) announced its quarterly earnings results on Wednesday, February, 23rd. The company reported $0.67 EPS for the quarte...
What guidance has PROG issued on next quarter's earnings?
PROG updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share (EPS) guidance of $3.250-$3.700 for t...
What price target have analysts set for PRG?
3 brokers have issued 12 month price objectives for PROG's stock. Their forecasts range from $42.00 to $58.00. On average, they anticipate PROG's s...
Who are PROG's key executives?
PROG's management team includes the following people: Mr. Steven A. Michaels , CEO, Pres & Director (Age 49, Pay $1.97M) ( LinkedIn Profile ) Mr...
Who are some of PROG's key competitors?
Some companies that are related to PROG include Air Lease (AL) , Triton International (TRTN) , Custom Truck One Source (CTOS) , McGrath RentCor...
What is PROG's stock symbol?
PROG trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRG."
Who are PROG's major shareholders?
PROG's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.65%), Vulcan Val...
What is the ticker symbol for Prog?
PROG trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRG."
What is the consensus rating for Prog?
PROG has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
What is the P/E ratio of Prog?
The P/E ratio of PROG is 12.80, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 12.76.
What is a prog?
PROG Holdings, Inc. (NYSE:PRG) is a financial technology holding company based in Salt Lake City, Utah with three business segments: Progressive Leasing, which offers lease-to-own transactions primarily to credit-challenged consumers through e-commerce and point-of-sale retail partners, via online, mobile, and in-store solutions; Vive Financial, which provides consumers who may not qualify for traditional prime lending with a variety of second-look, revolving credit products through private label and branded credit cards; and Four Technologies, which provides consumers of all credit backgrounds Buy Now, Pay Later (BNPL) options through four interest-free installments via its platform, Four.
Does Prog pay dividends?
PROG does not currently pay a dividend.
PROG earnings per share forecast
What is PROG 's earnings per share in the next 3 years based on estimates from 1 analyst?
PROG revenue forecast
What is PROG 's revenue in the next 3 years based on estimates from 1 analyst?
PROG revenue growth forecast
How is PROG forecast to perform vs Diagnostics & Research companies and vs the US market?
How many shares of Progenity are there in 2021?
(“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock.
Is Progenity stock volatile?
At the time of its initial public offering in 2020, the biotech company went for $13 a share, and the stock has been highly volatile because it is a retail investor favorite. It is the second time in less than a month that Progenity has taken off on a short-squeeze-fueled frenzy.
Can you make money playing progenity?
You can make money playing penny shares like Progenity (NASDAQ:PROG) stock. Just get out while the getting is good. Source: PopTika / Shutterstock.com Progenity stock has been subject to a short squeeze since late September when it was selling below $1/share. It opened Nov. 16 at almost $4. As of late October, about 14% of the shares were being held short. Trading volume in PROG stock has also been rising sharply, from about 18 million shares per day in late September to 156 million shares at th
Is Progenity stock a disappointment?
Progenity (NASDAQ:PROG) is a biotech firm focused on treatments and testing products for a variety of diseases. Historically, PROG stock has been a disappointment. Since its initial public offering (IPO) in 2020, shares dropped from $13 to a low of under $1 per share. Recently, however, Progenity enjoyed a big short squeeze that brought shares back to the $4 mark. Source: Shutterstock It appears that the momentum is fading, however. Shares have started to slide again. And a deeper look into the
What is the price target for Prog 2021?
On Nov 04, 2021 "Stephens" gave "" rating for PROG. The price target was set to $3.45+10.9% .
Is Progenity stock a sell signal?
The Progenity, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $3.24. On a fall, the stock will find some support from the long-term average at approximately $2.94. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Friday, June 25, 2021, and so far it has fallen -23.29%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD).
Is Bollinger Band stock high risk?
This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $1.18 between high and low, or 29.72%. For the last week, the stock has had a daily average volatility of 26.63% .
What is the Progenity Inc?
Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. Revenue source is from Innatal, Preparent, and pathology molecular testing. Recently announced $40 Million Private Placement (8-k) Launches strategic transformation by eliminating costs of...
Is RSI overbought?
RSI is at overbought conditions. However the trend seems to be strong therefore we expect continuation toward the next resistance which would be our entry price for short position. The target as in the chart. No financial advice
Does Prog give a few setups?
Depending on your trading plan, PROG gave a few setups. You could have been swinging this since OCT reversal on the 4 hour. Multiple Day Trades and scalp opportunities if you had it on your watch list or got it off a scanner. This came up on my pre-market scanner. I took profits on the first trade as it ran in that 4.25 area to the 5.00 area early in the AM when...
PROG Stock at a Glance
Going back to the beginning, in June 2020, Progenity priced its initial public offering (IPO) at $15 per share. Unfortunately, Progenity’s shares lost 12.5% of its value on the first day of public trading.
Smaller Can Be Better
Can a company actually improve by slimming down its operations? It’s definitely possible, and Progenity is proving it.
Another Patent for the Portfolio
Even while Progenity slims down its business and reduces its expenses, the company continues to announce new patents.
The Takeaway
As we’ve discovered, Progenity isn’t just patent-rich. The company is also capital-rich.
What is the business model of Progenity?
Progenity’s business model is one that is certainly intriguing to growth investors. The company focuses on noninvasive prenatal screening tests for women. These tests allow users to see whether any deformities or abnormalities exist with their unborn children. Thus, this is a company that has seen a lot of hype since its initial public offering (IPO) last year.
Does Chris MacDonald have any positions in the securities mentioned in this article?
On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Is biotech a high risk sector?
Now, the biotech sector happens to be filled with generally high-risk, high-reward plays. When such companies announce positive news, these stocks tend to pop to a greater degree than the overall market. However, in times of trouble, the declines can be rapid.
